Zhejiang CONBA Pharmaceutical Co Ltd Asset Resilience Ratio
Zhejiang CONBA Pharmaceutical Co Ltd asset resilience ratio. Zhejiang CONBA Pharmaceutical Co Ltd (600572) has an Asset Resilience Ratio of 0.02% as of March 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 600572 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Zhejiang CONBA Pharmaceutical Co Ltd (2001–2020)
Asset resilience ratio of Zhejiang CONBA Pharmaceutical Co Ltd from 2001 to 2020. This chart shows how Zhejiang CONBA Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Read 600572 total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Zhejiang CONBA Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 600572 current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.80 Million | 0.02% |
| Total Liquid Assets | CN¥1.80 Million | 0.02% |
Asset Resilience Insights
- Limited Liquidity: Zhejiang CONBA Pharmaceutical Co Ltd maintains only 0.02% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Zhejiang CONBA Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Zhejiang CONBA Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Ajanta Pharma Limited
NSE:AJANTPHARM |
Drug Manufacturers - Specialty & Generic | 14.99% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Porton Fine Chemicals Ltd
SHE:300363 |
Drug Manufacturers - Specialty & Generic | 6.85% |
|
Jubilant Pharmova Limited
NSE:JUBLPHARMA |
Drug Manufacturers - Specialty & Generic | 1.26% |
Zhejiang CONBA Pharmaceutical Co Ltd Asset Resilience Ratio by Year (2001–2020)
Zhejiang CONBA Pharmaceutical Co Ltd asset resilience ratio by year from 2001 to 2020. The table below shows the annual Asset Resilience Ratio data for Zhejiang CONBA Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2020-12-31 | 0.02% | CN¥1.80 Million ≈ $262.70K |
CN¥9.28 Billion ≈ $1.36 Billion |
-0.11pp |
| 2019-12-31 | 0.13% | CN¥13.04 Million ≈ $1.91 Million |
CN¥9.86 Billion ≈ $1.44 Billion |
-0.38pp |
| 2018-12-31 | 0.51% | CN¥54.87 Million ≈ $8.03 Million |
CN¥10.71 Billion ≈ $1.57 Billion |
-1.02pp |
| 2017-12-31 | 1.53% | CN¥144.02 Million ≈ $21.07 Million |
CN¥9.42 Billion ≈ $1.38 Billion |
+0.69pp |
| 2016-12-31 | 0.84% | CN¥71.48 Million ≈ $10.46 Million |
CN¥8.50 Billion ≈ $1.24 Billion |
+0.01pp |
| 2015-12-31 | 0.83% | CN¥79.23 Million ≈ $11.59 Million |
CN¥9.57 Billion ≈ $1.40 Billion |
+0.74pp |
| 2014-12-31 | 0.09% | CN¥5.50 Million ≈ $804.82K |
CN¥6.30 Billion ≈ $921.72 Million |
+0.08pp |
| 2008-12-31 | 0.00% | CN¥64.05K ≈ $9.37K |
CN¥1.57 Billion ≈ $229.63 Million |
-0.06pp |
| 2007-12-31 | 0.06% | CN¥935.55K ≈ $136.90K |
CN¥1.55 Billion ≈ $226.53 Million |
+0.04pp |
| 2006-12-31 | 0.02% | CN¥240.44K ≈ $35.18K |
CN¥1.26 Billion ≈ $183.77 Million |
+0.00pp |
| 2005-12-31 | 0.01% | CN¥171.72K ≈ $25.13K |
CN¥1.16 Billion ≈ $169.10 Million |
0.00pp |
| 2004-12-31 | 0.02% | CN¥167.78K ≈ $24.55K |
CN¥981.41 Million ≈ $143.61 Million |
-0.01pp |
| 2003-12-31 | 0.03% | CN¥174.31K ≈ $25.51K |
CN¥581.65 Million ≈ $85.11 Million |
-0.03pp |
| 2002-12-31 | 0.06% | CN¥269.97K ≈ $39.51K |
CN¥462.63 Million ≈ $67.70 Million |
-0.21pp |
| 2001-12-31 | 0.27% | CN¥1.22 Million ≈ $178.61K |
CN¥447.63 Million ≈ $65.50 Million |
-- |
About Zhejiang CONBA Pharmaceutical Co Ltd
Zhejiang CONBA Pharmaceutical Co.,Ltd. engages in the research, development, production, and sales of pharmaceuticals and health products in mainland China. It offers medicines, Chinese patent medicines, chemical medicines, Chinese herbal medicine slices, and health products. The company also provides Chinese decoction pieces; over-the-counter medications; healthy consumer products, including nut… Read more